Drag a card by its title · ⚙ to size, swap or remove

The company

NRC Health

NRC · Nasdaq

Health CareLife-science toolsIn trendAI

NRC stood above a rising 150-day average in 44 of the last 52 weekly readings, including each of the last 32 weeks. It is 3.5% above that average now. Life Science Tools & Research Services: 54% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation: In trend
Weeks in an uptrend: 32 in a row
Industry in uptrend: 54% +4 in 4 wk
Insider buys, 12 months: $196K
Insider sales, 12 months: $0
Officials’ trades on record: 0
Institutions holding: 115 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 44 of 52 weeks.

20 Apr – 19 Oct

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1

Sale orders, 12 months0

Buyers · sellers1 · 0

Who	Did	Shares	Traded
Shane R. HarrisonEVP & Chief Financial Officer	bought	8,000at $12.27	17 Feb 2026filed 19 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders115+2 on the quarter

New · exited17 · 14

Reported value$220.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLCreduced · filed 13 Aug 2026	2,030,492$43.8M	-605,863−23.0%
BlackRock, Inc.added · filed 7 Aug 2026	1,061,355$22.9M	+85,500+8.8%
MORGAN STANLEYreduced · filed 13 Aug 2026	859,269$18.5M	-142,611−14.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	666,554$14.4M	+3,717+0.6%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026	491,228$10.6M	+1,488+0.3%
Willis Investment Counseladded · filed 3 Aug 2026	434,785$9.4M	+210,147+93.5%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	420,056$9.1M	+26,209+6.7%
FARMERS & MERCHANTS INVESTMENTS INCadded · filed 20 Jul 2026	330,649$7.1M	+330,549+330549.0%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026	325,384$7.0M	-15,400−4.5%
HEARTLAND ADVISORS INCadded · filed 11 Aug 2026	300,000$6.5M	+62,853+26.5%

31 Mar 2023 – 30 Jun 2026

News

No headline names it lately.

Everyone who traded it

Donald M. Berwick Director · last 23 Jun 20260 · 18

John N. Nunnelly Director · last 23 Jun 20260 · 94

Parul Bhandari Director · last 23 Jun 20260 · 0

Penny Ann Wheeler Director · last 23 Jun 20260 · 0

Stephen H. Lockhart Director · last 23 Jun 20260 · 0

Jason Russell Rau Executive Vice President · last 12 Mar 20260 · 0

Shane R. Harrison EVP & Chief Financial Officer · last 17 Feb 20261 · 0

David Burik EVP, Strategic Insights · last 5 Jan 20260 · 0

Michael D. Hays Chairman · last 5 Jan 20262 · 86

Helen Hrdy EVP & Chief Operating Officer · last 15 Dec 20250 · 0

Jordan Nicole Freeman Chief Accounting Officer · last 31 Jul 20251 · 0

Trent S. Green Chief Executive Officer · last 1 Jun 20250 · 0

Same industry

OABI OmniAbLeading+67%

TXG 10x GenomicsLeading+59%

AVTR AvantorLeading+45%

ILMN IlluminaLeading+44%

RVTY RevvityLeading+35%

CRL Charles River Laboratories InternationalLeading+34%

MASS 908 DevicesLeading+32%

IQV IQVIA HoldingsLeading+27%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 202516.4%

Free cash flow marginFY 2025 · to 31 Dec 202511.5%

Return on capital employedFY 2025 · to 31 Dec 202523.0%

Debt to equityFY 2025 · to 31 Dec 20255.36×

Share count trendFY 2025 · to 28 Feb 20260.5%

Cash and equivalentsFY 2025 · to 31 Dec 2025$4.1M

Free cash flowFY 2025 · to 31 Dec 2025$15.7M

Analyst forecasts

No analyst forecasts yet.